Logo image of OMER

OMEROS CORP (OMER) Stock Fundamental Analysis

USA - NASDAQ:OMER - US6821431029 - Common Stock

6.87 USD
+0.14 (+2.08%)
Last: 11/5/2025, 2:39:53 PM
Fundamental Rating

0

OMER gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 192 industry peers in the Pharmaceuticals industry. OMER has a bad profitability rating. Also its financial health evaluation is rather negative. OMER has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year OMER has reported negative net income.
In the past year OMER has reported a negative cash flow from operations.
In multiple years OMER reported negative net income over the last 5 years.
In the past 5 years OMER reported 4 times negative operating cash flow.
OMER Yearly Net Income VS EBIT VS OCF VS FCFOMER Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

OMER has a worse Return On Assets (-61.06%) than 64.58% of its industry peers.
Industry RankSector Rank
ROA -61.06%
ROE N/A
ROIC N/A
ROA(3y)-26.61%
ROA(5y)-21.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OMER Yearly ROA, ROE, ROICOMER Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

OMER does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OMER Yearly Profit, Operating, Gross MarginsOMER Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for OMER has been reduced compared to 1 year ago.
The number of shares outstanding for OMER has been increased compared to 5 years ago.
The debt/assets ratio for OMER is higher compared to a year ago.
OMER Yearly Shares OutstandingOMER Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
OMER Yearly Total Debt VS Total AssetsOMER Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

OMER has an Altman-Z score of -8.50. This is a bad value and indicates that OMER is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -8.50, OMER is not doing good in the industry: 64.58% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.5
ROIC/WACCN/A
WACCN/A
OMER Yearly LT Debt VS Equity VS FCFOMER Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 0.81 indicates that OMER may have some problems paying its short term obligations.
OMER has a worse Current ratio (0.81) than 88.02% of its industry peers.
A Quick Ratio of 0.81 indicates that OMER may have some problems paying its short term obligations.
OMER has a worse Quick ratio (0.81) than 80.21% of its industry peers.
Industry RankSector Rank
Current Ratio 0.81
Quick Ratio 0.81
OMER Yearly Current Assets VS Current LiabilitesOMER Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

OMER shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.21%, which is quite good.
EPS 1Y (TTM)10.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

OMER is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.54% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.69%
EPS Next 2Y39.88%
EPS Next 3Y29.62%
EPS Next 5Y28.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OMER Yearly Revenue VS EstimatesOMER Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
OMER Yearly EPS VS EstimatesOMER Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OMER reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OMER is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OMER Price Earnings VS Forward Price EarningsOMER Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OMER Per share dataOMER EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3

4.3 Compensation for Growth

OMER's earnings are expected to grow with 29.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.88%
EPS Next 3Y29.62%

More info and screens

0

5. Dividend

5.1 Amount

OMER does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OMEROS CORP

NASDAQ:OMER (11/5/2025, 2:39:53 PM)

6.87

+0.14 (+2.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-05 2025-11-05
Inst Owners42.74%
Inst Owner Change0.07%
Ins Owners3.76%
Ins Owner Change-29.99%
Market Cap467.57M
Revenue(TTM)N/A
Net Income(TTM)-122474000
Analysts80
Price Target34.34 (399.85%)
Short Float %19.51%
Short Ratio3.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.01%
Min EPS beat(2)-0.35%
Max EPS beat(2)12.36%
EPS beat(4)3
Avg EPS beat(4)16.47%
Min EPS beat(4)-0.35%
Max EPS beat(4)31.91%
EPS beat(8)6
Avg EPS beat(8)19.22%
EPS beat(12)9
Avg EPS beat(12)55.32%
EPS beat(16)12
Avg EPS beat(16)46.64%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.22%
PT rev (3m)12.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.95%
EPS NY rev (1m)0.4%
EPS NY rev (3m)1.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.11
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-1.74
FCFYN/A
OCF(TTM)-1.74
OCFYN/A
SpS0
BVpS-3.36
TBVpS-3.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.61%
ROA(5y)-21.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.68%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.81
Quick Ratio 0.81
Altman-Z -8.5
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)25.18%
Cap/Depr(5y)22.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.67%
EPS Next Y28.69%
EPS Next 2Y39.88%
EPS Next 3Y29.62%
EPS Next 5Y28.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year75.27%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-231.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-231.21%
OCF growth 3YN/A
OCF growth 5YN/A

OMEROS CORP / OMER FAQ

What is the ChartMill fundamental rating of OMEROS CORP (OMER) stock?

ChartMill assigns a fundamental rating of 0 / 10 to OMER.


What is the valuation status for OMER stock?

ChartMill assigns a valuation rating of 1 / 10 to OMEROS CORP (OMER). This can be considered as Overvalued.


What is the profitability of OMER stock?

OMEROS CORP (OMER) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for OMER stock?

The Earnings per Share (EPS) of OMEROS CORP (OMER) is expected to grow by 28.69% in the next year.